A Bayesian method based on clotting factor activity for the prediction of maintenance warfarin dosage regimens

Therapeutic Drug Monitoring

Volumn 25, Issue 1, 2003, Pages 36-40

  Pitsiu, Maria ^a,b   Parker, Eva M ^a,b   Aarons, Leon ^a   Rowland, Malcolm ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Medeval Ltd   (United Kingdom)

Author keywords

Bayesian forecasting; Factor VII; Pharmacodynamics; Pharmacokinetics; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR; WARFARIN;

ALGORITHM; ANTICOAGULATION; ARTICLE; BAYES THEOREM; BLOOD CLOTTING; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER SIMULATION; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; MATHEMATICAL MODEL; NORMAL HUMAN; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RACEMIC MIXTURE; STEADY STATE;

ALGORITHMS; BAYES THEOREM; BLOOD COAGULATION FACTORS; DRUG ADMINISTRATION SCHEDULE; FORECASTING; HUMANS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; WARFARIN;

EID: 0037305998     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200302000-00005     Document Type: Article

References (29)

1. Sheiner LB. Computer-aided long term anticoagulation therapy. Comp Biomed Res 1969;2:507-18.
2. Theofanous T, Barille R. Multiple dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. J Pharm Sci 1973;62:261-6.
3. Abbrecht PH, O'Leary TJ, Behrentdt DM. Evaluation of a computer-assisted method for individualized anticoagulation: retrospective and prospective studies with a pharmacodynamic model. Clin Pharmacol Ther 1982;32:129-36.
4. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokin 1986;11:483-504.
5. Lee C, Coleman RW, Mungall D. Effect of using warfarin plasma concentrations in Bayesian forecasting of prothrombin-time response. Clin Pharm 1987;6:406-12.
6. Murray B, Coleman R, McWaters D, et al. Pharmacodynamics of warfarin at steady state. Ther Drug Monit 1987;9:1-5.
7. Boyle DA, Ludden TM Carter BI, et al. Evaluation of a Bayesian regression program for warfarin. Drug Intell Clin Pharm 1986;20:465.
8. Ovesen L, Lyduch S, Ott P. A simple technique for predicting maintenance dosage of warfarin - is it better than empirical dosing? Eur J Clin Pharmacol 1989;37:573-6.
9. McAleer SD, Chrystyn H. Bayesian derived pharmacokinetic/pharmacodynamic variables for warfarin therapy. Pharm Res 1990;7:F261.
10. Doi SAR. Pharmacodynamic optimization of warfarin therapy. Clin Pharmacol Ther 1994;55:597-601.
11. Poller L, Wright D, Rowlands M. Prospective comparative study of computer programs used for management of warfarin. J Clin Pathol 1993;46:299-303.
12. Vadher BD, Patterson DL, Leaning MS. Validation of an algorithm for oral anticoagulation dosing and appointment scheduling. Clin Lab Haematol 1995;17:339-45.
13. Svec JM, Coleman RW, Mungall DR, et al. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. Ther Drug Monit 1985;7:174-80.
14. Farrow L, Mungall D, Raskob G, et al. Predicting the daily prothrombin time response to warfarin. Ther Drug Monit 1990;12:246-9.
15. Narayanan MN, Lucas SB. A genetic algorithm to improve a neural network to predict a patient's response to warfarin. Methods Inf Med 1993;32:55-8.
16. Vigano-D'Angelo S, Comp PC, Emson CT, et al. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986;77:416-25.
17. Pitsiu M, Parker EM, Aarons L, et al. A comparison of the relative sensitivities of factor VII and prothrombin time measurements in detecting drug interactions with warafarin. Eur J Clin Pharmacol 1992;42:645-50.
18. Banfield C, Rowland M. Stereospecific fluorescence highperformance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. J Pharm Sci 1984;73:1392-6.
19. Breckenridge AM, Orme MLE. Kinetics of warfarin absorption in man. Clin Pharmacol Ther 1973;14:955-9.
20. 1 metabolism. Br J Clin Pharmacol 1986;22:729-32.
21. Bell RG, Ren P. Inhibition by warfarin enantiomers of prothrombin synthesis, protein carboxylation and the regeneration of vitamin K from vitamin K epoxide. Biochem Pharmacol 1981;30:1953-8.
22. Breckenridge AM. Interindividual differences in the response to oral anticoagulants. Drugs 1977;14:367-75.
23. Chan E, Pegg M, Mackay AD, et al. Stereochemical aspects of warfarin in patients receiving chronic therapy. Br J Clin Pharmacol 1987;19:571P.
24. Chan E, McLachlan A, O'Reilly R, et al. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokineticpharmacodynamic model. Clin Pharmacol Ther 1994;56:286-94.
25. O'Reilly RA. Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. Circulation 1982;65:202-7.
26. Sheiner LB, Beal SL. Bayesian individualisation of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982;71:1344-8.
27. Pitsiu M, Parker EM, Aarons L, et al. Population pharmacokinetics and pharmacodynamics of warfarin in young adults. Eur J Pharm Sci 1993;1:151-7.
28. Porter RS, Sawer WT, Lowenthal DT. Warfarin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. 2nd ed. Spokane: Applied Therapeutics, 1986:Ch. 31.
29. Grind M, Murphy M, Warrington S, et al. Method for studying drug-warfarin interactions. Clin Pharmacol Ther 1993;54:381-s7.